Fetuin-A and angiopoietins in obesity and type 2 diabetes mellitus

Endocrine

Volumn 42, Issue 3, 2012, Pages 496-505

  Rasul, Sazan ^a   Wagner, Ludwig ^a   Kautzky Willer, Alexandra ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Angiopoietins; Fetuin A; Obesity; Type 2 diabetes; Vascular diseases

Indexed keywords

ADIPONECTIN; ANGIOPOIETIN 1; ANGIOPOIETIN 2; ANGIOPOIETIN RECEPTOR; ANGIOTENSINOGEN; APELIN; C REACTIVE PROTEIN; CALCIUM; CHEMERIN; DIACYLGLYCEROL; FETUIN A; GLUCOSE; INTERLEUKIN 6; LEPTIN; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; PHOSPHATE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN KINASE C; RESISTIN; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN; ANGIOPOIETIN;

ADIPOSE TISSUE; ANGIOGENESIS; ATHEROSCLEROSIS; BLOOD VESSEL CALCIFICATION; BODY FAT; BODY MASS; BONE DENSITY; BONE MINERALIZATION; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; ENDOTHELIUM INJURY; HUMAN; HYPERGLYCEMIA; INSULIN RESISTANCE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; OSTEOLYSIS; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; VASCULAR DISEASE; METABOLISM; PATHOLOGY; PHYSIOLOGY;

ADIPOSE TISSUE; ALPHA-2-HS-GLYCOPROTEIN; ANGIOPOIETINS; DIABETES MELLITUS, TYPE 2; HUMANS; NEOVASCULARIZATION, PHYSIOLOGIC; OBESITY;

EID: 84878262050     PISSN: 1355008X     EISSN: 15590100     Source Type: Journal    
DOI: 10.1007/s12020-012-9754-4     Document Type: Review

References (123)

1. American Diabetes Association, Diagnosis and classification of diabetes mellitus. Diabetes Care 33(Suppl 1), S62-S69 (2010). doi: 10.2337/dc10-S062
2. L. Bellamy, J.P. Casas, A.D. Hingorani, D. Williams, Type 2 diabetes mellitus after gestational diabetes: a systematic review and meta-analysis. Lancet 373(9677), 1773-1779 (2009). doi: 10.1016/S0140-6736(09)60731-5
3. R.J. Chang, R.M. Nakamura, H.L. Judd, S.A. Kaplan, Insulin resistance in nonobese patients with polycystic ovarian disease. J. Clin. Endocrinol. Metab. 57(2), 356-359 (1983)
4. G.R. Hajer, T.W. van Haeften, F.L. Visseren, Adipose tissue dysfunction in obesity, diabetes, and vascular diseases. Eur. Heart J. 29(24), 2959-2971 (2008). doi: 10.1093/eurheartj/ehn387
5. N. Stefan, A.M. Hennige, H. Staiger, J. Machann, F. Schick, E. Schleicher, A. Fritsche, H.U. Haring, High circulating retinol-binding protein 4 is associated with elevated liver fat but not with total, subcutaneous, visceral, or intramyocellular fat in humans. Diabetes Care 30(5), 1173-1178 (2007). doi: 10.2337/dc06-2342
6. A. Seppala-Lindroos, S. Vehkavaara, A.M. Hakkinen, T. Goto, J. Westerbacka, A. Sovijarvi, J. Halavaara, H. Yki-Jarvinen, Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men. J. Clin. Endocrinol. Metab. 87(7), 3023-3028 (2002)
7. J.H. Hwang, D.T. Stein, N. Barzilai, M.H. Cui, J. Tonelli, P. Kishore, M. Hawkins, Increased intrahepatic triglyceride is associated with peripheral insulin resistance: in vivo MR imaging and spectroscopy studies. Am. J. Physiol. Endocrinol. Metab. 293(6), E1663-E1669 (2007). doi: 10.1152/ajpendo.00590.2006
8. E.J. de Belin Chantemele, D.W. Stepp, Influence of obesity and metabolic dysfunction on the endothelial control in the coronary circulation. J. Mol. Cell. Cardiol. 52(4), 840-847 (2012). doi: 10.1016/j.yjmcc.2011.08.018
9. J.B. Lindsey, F. Cipollone, S.M. Abdullah, D.K. McGuire, Receptor for advanced glycation end-products (RAGE) and soluble RAGE (sRAGE): cardiovascular implications. Diabetes Vasc. Dis. Res. 6(1), 7-14 (2009). doi: 10.3132/dvdr.2009.002
10. R. Westenfeld, C. Schafer, T. Kruger, C. Haarmann, L.J. Schurgers, C. Reutelingsperger, O. Ivanovski, T. Drueke, Z.A. Massy, M. Ketteler, J. Floege, W. Jahnen-Dechent, Fetuin-A protects against atherosclerotic calcification in CKD. J. Am. Soc. Nephrol. 20(6), 1264-1274 (2009). doi: 10.1681/ASN.2008060572
11. S. David, P. Kumpers, A. Lukasz, D. Fliser, J. Martens-Lobenhoffer, S.M. Bode-Boger, V. Kliem, H. Haller, J.T. Kielstein, Circulating angiopoietin-2 levels increase with progress of chronic kidney disease. Nephrol. Dial. Transplant. 25(8), 2571-2576 (2010). doi: 10.1093/ndt/gfq060
12. Obesity and Overweight. World Health Organization Fact sheet No. 311 (May 2012)
13. A. Rodriguez, V. Catalan, J. Gomez-Ambrosi, G. Fruhbeck, Visceral and subcutaneous adiposity: are both potential therapeutic targets for tackling the metabolic syndrome? Curr. Pharm. Des. 13(21), 2169-2175 (2007)
14. E.B. Geer, W. Shen, Gender differences in insulin resistance, body composition, and energy balance. Gend. Med. 6(Suppl 1), 60-75 (2009). doi: 10.1016/j.genm.2009.02.002
15. V. Mohamed-Ali, J.H. Pinkney, S.W. Coppack, Adipose tissue as an endocrine and paracrine organ. Int. J. Obes. Rel. Metab. Disord. 22(12), 1145-1158 (1998)
16. M. Pardo, A. Roca-Rivada, L.M. Seoane, F.F. Casanueva, Obesidomics: contribution of adipose tissue secretome analysis to obesity research. Endocrine 41(3), 374-383 (2012). doi: 10.1007/s12020-012-9617-z
17. I. Castan-Laurell, C. Dray, C. Attane, T. Duparc, C. Knauf, P. Valet, Apelin, diabetes, and obesity. Endocrine 40(1), 1-9 (2011). doi: 10.1007/s12020-011-9507-9
18. K. Brochu-Gaudreau, C. Rehfeldt, R. Blouin, V. Bordignon, B.D. Murphy, M.F. Palin, Adiponectin action from head to toe. Endocrine 37(1), 11-32 (2010). doi: 10.1007/s12020-009-9278-8
19. A.D. Pradhan, J.E. Manson, N. Rifai, J.E. Buring, P.M. Ridker, C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 286(3), 327-334 (2001)
20. N. Kubota, Y. Terauchi, T. Yamauchi, T. Kubota, M. Moroi, J. Matsui, K. Eto, T. Yamashita, J. Kamon, H. Satoh, W. Yano, P. Froguel, R. Nagai, S. Kimura, T. Kadowaki, T. Noda, Disruption of adiponectin causes insulin resistance and neointimal formation. J. Biol. Chem. 277(29), 25863-25866 (2002). doi: 10.1074/jbc.C200251200
21. J.V. Silha, M. Krsek, J.V. Skrha, P. Sucharda, B.L. Nyomba, L.J. Murphy, Plasma resistin, adiponectin and leptin levels in lean and obese subjects: correlations with insulin resistance. Eur. J. Endocrinol. 149(4), 331-335 (2003)
22. H. Xu, G.T. Barnes, Q. Yang, G. Tan, D. Yang, C.J. Chou, J. Sole, A. Nichols, J.S. Ross, L.A. Tartaglia, H. Chen, Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J. Clin. Investig. 112(12), 1821-1830 (2003). doi: 10.1172/JCI19451
23. M. Roden, Mechanisms of disease: hepatic steatosis in type 2 diabetes-pathogenesis and clinical relevance. Nat. Clin. Pract. Endocrinol. Metab. 2(6), 335-348 (2006). doi: 10.1038/ncpendmet0190
24. S.R. Weston, W. Leyden, R. Murphy, N.M. Bass, B.P. Bell, M.M. Manos, N.A. Terrault, Racial and ethnic distribution of nonalcoholic fatty liver in persons with newly diagnosed chronic liver disease. Hepatology 41(2), 372-379 (2005). doi: 10.1002/hep.20554
25. D.M. Ferreira, R.E. Castro, M.V. Machado, T. Evangelista, A. Silvestre, A. Costa, J. Coutinho, F. Carepa, H. Cortez-Pinto, C.M. Rodrigues, Apoptosis and insulin resistance in liver and peripheral tissues of morbidly obese patients is associated with different stages of non-alcoholic fatty liver disease. Diabetologia 54(7), 1788-1798 (2011). doi: 10.1007/s00125-011-2130-8
26. N. Villanova, S. Moscatiello, S. Ramilli, E. Bugianesi, D. Magalotti, E. Vanni, M. Zoli, G. Marchesini, Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease. Hepatology 42(2), 473-480 (2005). doi: 10.1002/hep.20781
27. E. Scorletti, P.C. Calder, C.D. Byrne, Non-alcoholic fatty liver disease and cardiovascular risk: metabolic aspects and novel treatments. Endocrine 40(3), 332-343 (2011). doi: 10.1007/s12020-011-9530-x
28. G. Marchesini, M. Brizi, G. Bianchi, S. Tomassetti, E. Bugianesi, M. Lenzi, A.J. McCullough, S. Natale, G. Forlani, N. Melchionda, Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 50(8), 1844-1850 (2001)
29. K. Kantartzis, J. Machann, F. Schick, A. Fritsche, H.U. Haring, N. Stefan, The impact of liver fat vs visceral fat in determining categories of prediabetes. Diabetologia 53(5), 882-889 (2010). doi: 10.1007/s00125-010-1663-6
30. G. Marchesini, E. Bugianesi, G. Forlani, F. Cerrelli, M. Lenzi, R. Manini, S. Natale, E. Vanni, N. Villanova, N. Melchionda, M. Rizzetto, Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 37(4), 917-923 (2003). doi: 10.1053/jhep.2003.50161
31. G. Rauth, O. Poschke, E. Fink, M. Eulitz, S. Tippmer, M. Kellerer, H.U. Haring, P. Nawratil, M. Haasemann, W. Jahnen-Dechent et al., The nucleotide and partial amino acid sequences of rat fetuin. Identity with the natural tyrosine kinase inhibitor of the rat insulin receptor. Eur. J. Biochem. 204(2), 523-529 (1992)
32. P. Auberger, L. Falquerho, J.O. Contreres, G. Pages, G. Le Cam, B. Rossi, A. Le Cam, Characterization of a natural inhibitor of the insulin receptor tyrosine kinase: cDNA cloning, purification, and anti-mitogenic activity. Cell 58(4), 631-640 (1989)
33. N. Stefan, A. Fritsche, C. Weikert, H. Boeing, H.G. Joost, H.U. Haring, M.B. Schulze, Plasma fetuin-A levels and the risk of type 2 diabetes. Diabetes 57(10), 2762-2767 (2008). doi: 10.2337/db08-0538
34. S.T. Mathews, S. Rakhade, X. Zhou, G.C. Parker, D.V. Coscina, G. Grunberger, Fetuin-null mice are protected against obesity and insulin resistance associated with aging. Biochem. Biophys. Res. Commun. 350(2), 437-443 (2006). doi: 10.1016/j.bbrc.2006.09.071
35. J.H. Ix, C.L. Wassel, A.M. Kanaya, E. Vittinghoff, K.C. Johnson, A. Koster, J.A. Cauley, T.B. Harris, S.R. Cummings, M.G. Shlipak, Health ABC Study, Fetuin-A and incident diabetes mellitus in older persons. JAMA 300(2), 182-188 (2008). doi: 10.1001/jama.300.2.182
36. J.H. Ix, M.L. Biggs, K.J. Mukamal, J.R. Kizer, S.J. Zieman, D.S. Siscovick, D. Mozzaffarian, M.K. Jensen, L. Nelson, N. Ruderman, L. Djousse, Association of fetuin-a with incident diabetes mellitus in community-living older adults: the cardiovascular health study. Circulation 125(19), 2316-2322 (2012). doi: 10.1161/CIRCULATIONAHA.111.072751
37. A. Ishibashi, Y. Ikeda, T. Ohguro, Y. Kumon, S. Yamanaka, H. Takata, M. Inoue, T. Suehiro, Y. Terada, Serum fetuin-A is an independent marker of insulin resistance in Japanese men. J. Atheroscler. Thromb. 17(9), 925-933 (2010)
38. S. Rasul, A. Ilhan, M.H. Reiter, J. Todoric, S. Farhan, H. Esterbauer, A. Kautzky-Willer, Levels of fetuin-A relate to the levels of bone turnover biomarkers in male and female patients with type 2 diabetes. Clin. Endocrinol. 76(4), 499-505 (2012). doi: 10.1111/j.1365-2265.2011.04246.x
39. K. Mori, M. Emoto, H. Yokoyama, T. Araki, M. Teramura, H. Koyama, T. Shoji, M. Inaba, Y. Nishizawa, Association of serum fetuin-A with insulin resistance in type 2 diabetic and nondiabetic subjects. Diabetes Care 29(2), 468 (2006)
40. X. Lin, H.D. Braymer, G.A. Bray, D.A. York, Differential expression of insulin receptor tyrosine kinase inhibitor (fetuin) gene in a model of diet-induced obesity. Life Sci. 63(2), 145-153 (1998)
41. S.T. Mathews, G.P. Singh, M. Ranalletta, V.J. Cintron, X. Qiang, A.S. Goustin, K.L. Jen, M.J. Charron, W. Jahnen-Dechent, G. Grunberger, Improved insulin sensitivity and resistance to weight gain in mice null for the Ahsg gene. Diabetes 51(8), 2450-2458 (2002)
42. J.H. Ix, M.G. Shlipak, V.M. Brandenburg, S. Ali, M. Ketteler, M.A. Whooley, Association between human fetuin-A and the metabolic syndrome: data from the heart and soul study. Circulation 113(14), 1760-1767 (2006). doi: 10.1161/CIRCULATIONAHA.105.588723
43. S. Farhan, A. Handisurya, J. Todoric, A. Tura, G. Pacini, O. Wagner, K. Klein, R. Jarai, K. Huber, A. Kautzky-Willer, Fetuin-A characteristics during and after pregnancy: result from a case control pilot study. Int. J. Endocrinol. 2012, 896736 (2012). doi: 10.1155/2012/896736
44. J.M. Brix, H. Stingl, F. Hollerl, G.H. Schernthaner, H.P. Kopp, G. Schernthaner, Elevated Fetuin-A concentrations in morbid obesity decrease after dramatic weight loss. J. Clin. Endocrinol. Metab. 95(11), 4877-4881 (2010). doi: 10.1210/jc.2010-0148
45. T. Reinehr, C.L. Roth, Fetuin-A and its relation to metabolic syndrome and fatty liver disease in obese children before and after weight loss. J. Clin. Endocrinol. Metab. 93(11), 4479-4485 (2008). doi: 10.1210/jc.2008-1505
46. N.T. Jenkins, J.A. McKenzie, J.M. Hagberg, S. Witkowski, Plasma fetuin-A concentrations in young and older high- and low-active men. Metab. Clin. Exp. 60(2), 265-271 (2011). doi: 10.1016/j.metabol.2010.01.026
47. A.M. Hennige, H. Staiger, C. Wicke, F. Machicao, A. Fritsche, H.U. Haring, N. Stefan, Fetuin-A induces cytokine expression and suppresses adiponectin production. PLoS One 3(3), e1765 (2008). doi: 10.1371/journal.pone. 0001765
48. J.W. Haukeland, T.B. Dahl, A. Yndestad, I.P. Gladhaug, E.M. Loberg, T. Haaland, Z. Konopski, C. Wium, E.T. Aasheim, O.E. Johansen, P. Aukrust, B. Halvorsen, K.I. Birkeland, Fetuin A in nonalcoholic fatty liver disease: in vivo and in vitro studies. Eur. J. Endocrinol. 166(3), 503-510 (2012). doi: 10.1530/EJE-11-0864
49. N. Stefan, A.M. Hennige, H. Staiger, J. Machann, F. Schick, S.M. Krober, F. Machicao, A. Fritsche, H.U. Haring, Alpha2-Heremans-Schmid glycoprotein/fetuin-A is associated with insulin resistance and fat accumulation in the liver in humans. Diabetes Care 29(4), 853-857 (2006)
50. K. Mussig, H. Staiger, F. Machicao, J. Machann, A.M. Hennige, F. Schick, C.D. Claussen, A. Fritsche, H.U. Haring, N. Stefan, AHSG gene variation is not associated with regional body fat distribution - a magnetic resonance study. Exp. Clin. Endocrinol. Diabetes 117(8), 432-437 (2009). doi: 10.1055/s-0028-1103299
51. Y. Yilmaz, O. Yonal, R. Kurt, F. Ari, A.Y. Oral, C.A. Celikel, S. Korkmaz, E. Ulukaya, O. Ozdogan, N. Imeryuz, E. Avsar, C. Kalayci, Serum fetuin A/alpha2HS-glycoprotein levels in patients with non-alcoholic fatty liver disease: relation with liver fibrosis. Ann. Clin. Biochem. 47(Pt 6), 549-553 (2010). doi: 10.1258/acb.2010.010169
52. A. Kotronen, H. Yki-Jarvinen, Fatty liver: a novel component of the metabolic syndrome. Arterioscler. Thromb. Vasc. Biol. 28(1), 27-38 (2008). doi: 10.1161/ATVBAHA.107.147538
53. S.H. Park, B.I. Kim, J.W. Yun, J.W. Kim, D.I. Park, Y.K. Cho, I.K. Sung, C.Y. Park, C.I. Sohn, W.K. Jeon, H. Kim, E.J. Rhee, W.Y. Lee, S.W. Kim, Insulin resistance and C-reactive protein as independent risk factors for non-alcoholic fatty liver disease in non-obese Asian men. J. Gastroenterol. Hepatol. 19(6), 694-698 (2004). doi: 10.1111/j.1440-1746.2004.03362.x
54. J.M. Hui, A. Hodge, G.C. Farrell, J.G. Kench, A. Kriketos, J. George, Beyond insulin resistance in NASH: tNF-alpha or adiponectin? Hepatology 40(1), 46-54 (2004). doi: 10.1002/hep.20280
55. S. Bellentani, G. Saccoccio, F. Masutti, L.S. Croce, G. Brandi, F. Sasso, G. Cristanini, C. Tiribelli, Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann. Intern. Med. 132(2), 112-117 (2000)
56. N. Vionnet, E.H. Hani, S. Dupont, S. Gallina, S. Francke, S. Dotte, F. De Matos, E. Durand, F. Lepretre, C. Lecoeur, P. Gallina, L. Zekiri, C. Dina, P. Froguel, Genomewide search for type 2 diabetes-susceptibility genes in French whites: evidence for a novel susceptibility locus for early-onset diabetes on chromosome 3q27-qter and independent replication of a type 2-diabetes locus on chromosome 1q21-q24. Am. J. Hum. Genet. 67(6), 1470-1480 (2000). doi: 10.1086/316887
57. J. Folkman, Angiogenesis-dependent diseases. Semin. Oncol. 28(6), 536-542 (2001)
58. D.A. Walsh, C.I. Pearson, Angiogenesis in the pathogenesis of inflammatory joint and lung diseases. Arthr. Res. 3(3), 147-153 (2001)
59. M.A. Rupnick, D. Panigrahy, C.Y. Zhang, S.M. Dallabrida, B.B. Lowell, R. Langer, M.J. Folkman, Adipose tissue mass can be regulated through the vasculature. Proc. Natl. Acad. Sci. U.S.A. 99(16), 10730-10735 (2002). doi: 10.1073/pnas.162349799
60. N.P. Fam, S. Verma, M. Kutryk, D.J. Stewart, Clinician guide to angiogenesis. Circulation 108(21), 2613-2618 (2003). doi: 10.1161/01.CIR. 0000102939.04279.75
61. U. Fiedler, H.G. Augustin, Angiopoietins: a link between angiogenesis and inflammation. Trends Immunol. 27(12), 552-558 (2006). doi: 10.1016/j.it.2006. 10.004
62. F. Shalaby, J. Rossant, T.P. Yamaguchi, M. Gertsenstein, X.F. Wu, M.L. Breitman, A.C. Schuh, Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature 376(6535), 62-66 (1995). doi: 10.1038/376062a0
63. P.C. Maisonpierre, C. Suri, P.F. Jones, S. Bartunkova, S.J. Wiegand, C. Radziejewski, D. Compton, J. McClain, T.H. Aldrich, N. Papadopoulos, T.J. Daly, S. Davis, T.N. Sato, G.D. Yancopoulos, Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 277(5322), 55-60 (1997)
64. J.X. Chen, A. Stinnett, Disruption of Ang-1/Tie-2 signaling contributes to the impaired myocardial vascular maturation and angiogenesis in type II diabetic mice. Arterioscler. Thromb. Vasc. Biol. 28(9), 1606-1613 (2008). doi: 10.1161/ATVBAHA.108.169235
65. D. Watanabe, K. Suzuma, I. Suzuma, H. Ohashi, T. Ojima, M. Kurimoto, T. Murakami, T. Kimura, H. Takagi, Vitreous levels of angiopoietin 2 and vascular endothelial growth factor in patients with proliferative diabetic retinopathy. Am. J. Ophthalmol. 139(3), 476-481 (2005). doi: 10.1016/j.ajo.2004.10.004
66. A.Y. Chong, G.J. Caine, B. Freestone, A.D. Blann, G.Y. Lip, Plasma angiopoietin-1, angiopoietin-2, and angiopoietin receptor tie-2 levels in congestive heart failure. J. Am. Coll. Cardiol. 43(3), 423-428 (2004). doi: 10.1016/j.jacc.2003.08.042
67. S. Anuradha, V. Mohan, K. Gokulakrishnan, M. Dixit, Angiopoietin-2 levels in glucose intolerance, hypertension, and metabolic syndrome in Asian Indians (Chennai Urban Rural Epidemiology Study-74). Metab. Clin. Exp. 59(6), 774-779 (2010). doi: 10.1016/j.metabol.2009.09.022
68. Y.C. Chung, Y.C. Hou, C.N. Chang, T.H. Hseu, Expression and prognostic significance of angiopoietin in colorectal carcinoma. J. Surg. Oncol. 94(7), 631-638 (2006). doi: 10.1002/jso.20423
69. S. Rasul, M.H. Reiter, A. Ilhan, K. Lampichler, L. Wagner, A. Kautzky-Willer, Circulating angiopoietin-2 and soluble Tie-2 in type 2 diabetes mellitus: a cross-sectional study. Cardiovasc. Diabetol. 10, 55 (2011). doi: 10.1186/1475-2840-10-55
70. W. Lieb, J.P. Zachariah, V. Xanthakis, R. Safa, M.H. Chen, L.M. Sullivan, M.G. Larson, H.M. Smith, Q. Yang, G.F. Mitchell, J.A. Vita, D.B. Sawyer, R.S. Vasan, Clinical and genetic correlates of circulating angiopoietin-2 and soluble Tie-2 in the community. Circ. Cardiovasc. Genet. 3(3), 300-306 (2010). doi: 10.1161/CIRCGENETICS.109.914556
71. J.V. Silha, M. Krsek, P. Sucharda, L.J. Murphy, Angiogenic factors are elevated in overweight and obese individuals. Int. J. Obes. 29(11), 1308-1314 (2005). doi: 10.1038/sj.ijo.0802987
72. H.O. Steinberg, G. Paradisi, J. Cronin, K. Crowde, A. Hempfling, G. Hook, A.D. Baron, Type II diabetes abrogates sex differences in endothelial function in premenopausal women. Circulation 101(17), 2040-2046 (2000)
73. Y. Yamamoto, I. Kato, T. Doi, H. Yonekura, S. Ohashi, M. Takeuchi, T. Watanabe, S. Yamagishi, S. Sakurai, S. Takasawa, H. Okamoto, H. Yamamoto, Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice. J. Clin. Investig. 108(2), 261-268 (2001). doi: 10.1172/JCI11771
74. T. Okamoto, S. Yamagishi, Y. Inagaki, S. Amano, K. Koga, R. Abe, M. Takeuchi, S. Ohno, A. Yoshimura, Z. Makita, Angiogenesis induced by advanced glycation end products and its prevention by cerivastatin. FASEB J. 16(14), 1928-1930 (2002). doi: 10.1096/fj.02-0030fje
75. B. Williams, B. Gallacher, H. Patel, C. Orme, Glucose-induced protein kinase C activation regulates vascular permeability factor mRNA expression and peptide production by human vascular smooth muscle cells in vitro. Diabetes 46(9), 1497-1503 (1997)
76. X.L. Du, D. Edelstein, L. Rossetti, I.G. Fantus, H. Goldberg, F. Ziyadeh, J. Wu, M. Brownlee, Hyperglycemia-induced mitochondrial superoxide overproduction activates the hexosamine pathway and induces plasminogen activator inhibitor-1 expression by increasing Sp1 glycosylation. Proc. Natl. Acad. Sci. U.S.A. 97(22), 12222-12226 (2000). doi: 10.1073/pnas.97.22.12222
77. H.S. Lim, G.Y. Lip, A.D. Blann, Angiopoietin-1 and angiopoietin-2 in diabetes mellitus: relationship to VEGF, glycaemic control, endothelial damage/dysfunction and atherosclerosis. Atherosclerosis 180(1), 113-118 (2005). doi: 10.1016/j.atherosclerosis.2004.11.004
78. J.X. Chen, H. Zeng, J. Reese, J.L. Aschner, B. Meyrick, Overexpression of angiopoietin-2 impairs myocardial angiogenesis and exacerbates cardiac fibrosis in the diabetic db/db mouse model. Am. J. Physiol. Heart Circ. Physiol. 302(4), H1003-H1012 (2012). doi: 10.1152/ajpheart.00866.2011
79. Q.H. Tuo, H. Zeng, A. Stinnett, H. Yu, J.L. Aschner, D.F. Liao, J.X. Chen, Critical role of angiopoietins/Tie-2 in hyperglycemic exacerbation of myocardial infarction and impaired angiogenesis. Am. J. Physiol. Heart Circ. Physiol. 294(6), H2547-H2557 (2008). doi: 10.1152/ajpheart.01250.2007
80. H.P. Hammes, J. Lin, P. Wagner, Y. Feng, F. Vom Hagen, T. Krzizok, O. Renner, G. Breier, M. Brownlee, U. Deutsch, Angiopoietin-2 causes pericyte dropout in the normal retina: evidence for involvement in diabetic retinopathy. Diabetes 53(4), 1104-1110 (2004)
81. X. Cui, M. Chopp, A. Zacharek, X. Ye, C. Roberts, J. Chen, Angiopoietin/Tie2 pathway mediates type 2 diabetes induced vascular damage after cerebral stroke. Neurobiol. Dis. 43(1), 285-292 (2011). doi: 10.1016/j.nbd.2011.04.005
82. S. Calderari, C. Chougnet, M. Clemessy, H. Kempf, P. Corvol, E. Larger, Angiopoietin 2 alters pancreatic vascularization in diabetic conditions. PLoS One 7(1), e29438 (2012). doi: 10.1371/journal.pone.0029438
83. D. Yao, T. Taguchi, T. Matsumura, R. Pestell, D. Edelstein, I. Giardino, G. Suske, N. Rabbani, P.J. Thornalley, V.P. Sarthy, H.P. Hammes, M. Brownlee, High glucose increases angiopoietin-2 transcription in microvascular endothelial cells through methylglyoxal modification of mSin3A. J. Biol. Chem. 282(42), 31038-31045 (2007). doi: 10.1074/jbc.M704703200
84. H. Kampfer, J. Pfeilschifter, S. Frank, Expressional regulation of angiopoietin-1 and -2 and the tie-1 and -2 receptor tyrosine kinases during cutaneous wound healing: a comparative study of normal and impaired repair. Lab. Investig. 81(3), 361-373 (2001)
85. L. Qiao, S.L. Lu, J.Y. Dong, F. Song, Abnormal regulation of neo-vascularisation in deep partial thickness scalds in rats with diabetes mellitus. Burns 37(6), 1015-1022 (2011). doi: 10.1016/j.burns.2011.03.020
86. H. Singh, N.P. Brindle, V.A. Zammit, High glucose and elevated fatty acids suppress signaling by the endothelium protective ligand angiopoietin-1. Microvasc. Res. 79(2), 121-127 (2010). doi: 10.1016/j.mvr.2010.01.005
87. M. Brissova, A. Shostak, M. Shiota, P.O. Wiebe, G. Poffenberger, J. Kantz, Z. Chen, C. Carr, W.G. Jerome, J. Chen, H.S. Baldwin, W. Nicholson, D.M. Bader, T. Jetton, M. Gannon, A.C. Powers, Pancreatic islet production of vascular endothelial growth factor - a is essential for islet vascularization, revascularization, and function. Diabetes 55(11), 2974-2985 (2006). doi: 10.2337/db06-0690
88. Q.H. Tuo, G.Z. Xiong, H. Zeng, H.D. Yu, S.W. Sun, H.Y. Ling, B.Y. Zhu, D.F. Liao, J.X. Chen, Angiopoietin-1 protects myocardial endothelial cell function blunted by angiopoietin-2 and high glucose condition. Acta Pharmacol. Sin. 32(1), 45-51 (2011). doi: 10.1038/aps.2010.183
89. D. Su, N. Zhang, J. He, S. Qu, S. Slusher, R. Bottino, S. Bertera, J. Bromberg, H.H. Dong, Angiopoietin-1 production in islets improves islet engraftment and protects islets from cytokine-induced apoptosis. Diabetes 56(9), 2274-2283 (2007). doi: 10.2337/db07-0371
90. P. Mathieu, P. Pibarot, E. Larose, P. Poirier, A. Marette, J.P. Despres, Visceral obesity and the heart. Int. J. Biochem. Cell Biol. 40(5), 821-836 (2008). doi: 10.1016/j.biocel.2007.12.001
91. D.L. Crandall, G.J. Hausman, J.G. Kral, A review of the microcirculation of adipose tissue: anatomic, metabolic, and angiogenic perspectives. Microcirculation 4(2), 211-232 (1997)
92. P.A. Kern, G.B. Di Gregorio, T. Lu, N. Rassouli, G. Ranganathan, Adiponectin expression from human adipose tissue: relation to obesity, insulin resistance, and tumor necrosis factor-alpha expression. Diabetes 52(7), 1779-1785 (2003)
93. N. Maeda, I. Shimomura, K. Kishida, H. Nishizawa, M. Matsuda, H. Nagaretani, N. Furuyama, H. Kondo, M. Takahashi, Y. Arita, R. Komuro, N. Ouchi, S. Kihara, Y. Tochino, K. Okutomi, M. Horie, S. Takeda, T. Aoyama, T. Funahashi, Y. Matsuzawa, Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat. Med. 8(7), 731-737 (2002). doi: 10.1038/nm724
94. E. Brakenhielm, N. Veitonmaki, R. Cao, S. Kihara, Y. Matsuzawa, B. Zhivotovsky, T. Funahashi, Y. Cao, Adiponectin-induced antiangiogenesis and antitumor activity involve caspase-mediated endothelial cell apoptosis. Proc. Natl. Acad. Sci. U.S.A. 101(8), 2476-2481 (2004)
95. M. Kumada, S. Kihara, S. Sumitsuji, T. Kawamoto, S. Matsumoto, N. Ouchi, Y. Arita, Y. Okamoto, I. Shimomura, H. Hiraoka, T. Nakamura, T. Funahashi, Y. Matsuzawa, Osaka CAD Study Group. Coronary Artery Disease, Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler. Thromb. Vasc. Biol. 23(1), 85-89 (2003)
96. S. Rasul, A. Ilhan, M.H. Reiter, S. Baumgartner-Parzer, A. Kautzky-Willer, Relations of adiponectin to levels of metabolic parameters and sexual hormones in elderly type 2 diabetic patients. Gend. Med. 8(2), 93-102 (2011). doi: 10.1016/j.genm.2011.01.004
97. A. Gastaldelli, M. Kozakova, K. Hojlund, A. Flyvbjerg, A. Favuzzi, A. Mitrakou, B. Balkau, RISC Investigators, Fatty liver is associated with insulin resistance, risk of coronary heart disease, and early atherosclerosis in a large European population. Hepatology 49(5), 1537-1544 (2009). doi: 10.1002/hep.22845
98. I. Edirisinghe, K. McCormick Hallam, C.T. Kappagoda, Effect of fatty acids on endothelium-dependent relaxation in the rabbit aorta. Clin. Sci. 111(2), 145-151 (2006). doi: 10.1042/CS20060001
99. M.T. Nguyen, S. Favelyukis, A.K. Nguyen, D. Reichart, P.A. Scott, A. Jenn, R. Liu-Bryan, C.K. Glass, J.G. Neels, J.M. Olefsky, A subpopulation of macrophages infiltrates hypertrophic adipose tissue and is activated by free fatty acids via Toll-like receptors 2 and 4 and JNK-dependent pathways. J. Biol. Chem. 282(48), 35279-35292 (2007). doi: 10.1074/jbc.M706762200
100. J.S. Yudkin, M. Kumari, S.E. Humphries, V. Mohamed-Ali, Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? Atherosclerosis 148(2), 209-214 (2000)
101. M.Y. Abeywardena, W.R. Leifert, K.E. Warnes, J.N. Varghese, R.J. Head, Cardiovascular biology of interleukin-6. Curr. Pharm. Des. 15(15), 1809-1821 (2009)
102. N. Ouchi, S. Kihara, T. Funahashi, T. Nakamura, M. Nishida, M. Kumada, Y. Okamoto, K. Ohashi, H. Nagaretani, K. Kishida, H. Nishizawa, N. Maeda, H. Kobayashi, H. Hiraoka, Y. Matsuzawa, Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue. Circulation 107(5), 671-674 (2003)
103. Emerging Risk Factors Collaboration, S. Kaptoge, E. Di Angelantonio, G. Lowe, M.B. Pepys, S.G. Thompson, R. Collins, J. Danesh, C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet 375(9709), 132-140 (2010). doi: 10.1016/S0140-6736(09)61717-7
104. Y. Momiyama, R. Ohmori, Z.A. Fayad, T. Kihara, N. Tanaka, R. Kato, H. Taniguchi, M. Nagata, H. Nakamura, F. Ohsuzu, Associations between plasma C-reactive protein levels and the severities of coronary and aortic atherosclerosis. J. Atheroscler. Thromb. 17(5), 460-467 (2010)
105. U. Fiedler, Y. Reiss, M. Scharpfenecker, V. Grunow, S. Koidl, G. Thurston, N.W. Gale, M. Witzenrath, S. Rosseau, N. Suttorp, A. Sobke, M. Herrmann, K.T. Preissner, P. Vajkoczy, H.G. Augustin, Angiopoietin-2 sensitizes endothelial cells to TNF-alpha and has a crucial role in the induction of inflammation. Nat. Med. 12(2), 235-239 (2006). doi: 10.1038/nm1351
106. E. Volkova, J.A. Willis, J.E. Wells, B.A. Robinson, G.U. Dachs, M.J. Currie, Association of angiopoietin-2, C-reactive protein and markers of obesity and insulin resistance with survival outcome in colorectal cancer. Br. J. Cancer 104(1), 51-59 (2011). doi: 10.1038/sj.bjc.6606005
107. M. Skopkova, A. Penesova, H. Sell, Z. Radikova, M. Vlcek, R. Imrich, J. Koska, J. Ukropec, J. Eckel, I. Klimes, D. Gasperikova, Protein array reveals differentially expressed proteins in subcutaneous adipose tissue in obesity. Obesity 15(10), 2396-2406 (2007). doi: 10.1038/oby.2007.285
108. Z. Wang, T. Nakayama, Inflammation, a link between obesity and cardiovascular disease. Mediators Inflamm. 2010, 535918 (2010). doi: 10.1155/2010/535918
109. A. Heiss, A. DuChesne, B. Denecke, J. Grotzinger, K. Yamamoto, T. Renne, W. Jahnen-Dechent, Structural basis of calcification inhibition by alpha 2-HS glycoprotein/fetuin-A. Formation of colloidal calciprotein particles. J. Biol. Chem. 278(15), 13333-13341 (2003). doi: 10.1074/jbc.M210868200
110. D. Toroian, P.A. Price, The essential role of fetuin in the serum-induced calcification of collagen. Calcif. Tissue Int. 82(2), 116-126 (2008). doi: 10.1007/s00223-007-9085-2
111. J.H. Ix, C.L. Wassel, D.C. Bauer, D. Toroian, F.A. Tylavsky, J.A. Cauley, T.B. Harris, P.A. Price, S.R. Cummings, M.G. Shlipak, Health ABC Study, Fetuin-A and BMD in older persons: the Health Aging and Body Composition (Health ABC) study. J. Bone Miner. Res. 24(3), 514-521 (2009). doi: 10.1359/jbmr.081017
112. L. Chailurkit, A. Kruavit, R. Rajatanavin, B. Ongphiphadhanakul, The relationship of fetuin-A and lactoferrin with bone mass in elderly women. Osteoporosis Int. 22(7), 2159-2164 (2011). doi: 10.1007/s00198-010-1439-3
113. C. Schafer, A. Heiss, A. Schwarz, R. Westenfeld, M. Ketteler, J. Floege, W. Muller-Esterl, T. Schinke, W. Jahnen-Dechent, The serum protein alpha 2-Heremans-Schmid glycoprotein/fetuin-A is a systemically acting inhibitor of ectopic calcification. J. Clin. Investig. 112(3), 357-366 (2003). doi: 10.1172/JCI17202
114. T. Schinke, C. Amendt, A. Trindl, O. Poschke, W. Muller-Esterl, W. Jahnen-Dechent, The serum protein alpha2-HS glycoprotein/fetuin inhibits apatite formation in vitro and in mineralizing calvaria cells. A possible role in mineralization and calcium homeostasis. J. Biol. Chem. 271(34), 20789-20796 (1996)
115. P.A. Price, J.E. Lim, The inhibition of calcium phosphate precipitation by fetuin is accompanied by the formation of a fetuin-mineral complex. J. Biol. Chem. 278(24), 22144-22152 (2003). doi: 10.1074/jbc.M300744200
116. R.C. Shroff, V. Shah, M.P. Hiorns, M. Schoppet, L.C. Hofbauer, G. Hawa, L.J. Schurgers, A. Singhal, I. Merryweather, P. Brogan, C. Shanahan, J. Deanfield, L. Rees, The circulating calcification inhibitors, fetuin-A and osteoprotegerin, but not matrix Gla protein, are associated with vascular stiffness and calcification in children on dialysis. Nephrol. Dial. Transplant. 23(10), 3263-3271 (2008). doi: 10.1093/ndt/gfn226
117. A. Kirkpantur, B. Altun, T. Hazirolan, D. Akata, M. Arici, S. Kirazli, C. Turgan, Association among serum fetuin-A level, coronary artery calcification, and bone mineral densitometry in maintenance hemodialysis patients. Artif. Organs 33(10), 844-854 (2009). doi: 10.1111/j.1525-1594.2009.00814.x
118. M. Wang, M. Wang, L.Y. Gan, S.J. Li, N. Hong, M. Zhang, Vascular calcification in maintenance hemodialysis patients. Blood Purif. 28(1), 15-20 (2009). doi: 10.1159/000210033
119. J.H. Ix, R. Katz, I.H. de Boer, B.R. Kestenbaum, C.A. Peralta, N.S. Jenny, M. Budoff, M.A. Allison, M.H. Criqui, D. Siscovick, M.G. Shlipak, Fetuin-A is inversely associated with coronary artery calcification in community-living persons: the Multi-Ethnic Study of Atherosclerosis. Clin. Chem. 58(5), 887-895 (2012). doi: 10.1373/clinchem.2011.177725
120. J.H. Ix, E. Barrett-Connor, C.L. Wassel, K. Cummins, J. Bergstrom, L.B. Daniels, G.A. Laughlin, The associations of fetuin-A with subclinical cardiovascular disease in community-dwelling persons: the Rancho Bernardo Study. J. Am. Coll. Cardiol. 58(23), 2372-2379 (2011). doi: 10.1016/j.jacc.2011.08.035
121. E. Fisher, N. Stefan, K. Saar, D. Drogan, M.B. Schulze, A. Fritsche, H.G. Joost, H.U. Haring, N. Hubner, H. Boeing, C. Weikert, Association of AHSG gene polymorphisms with fetuin-A plasma levels and cardiovascular diseases in the EPIC-Potsdam study. Circul. Cardiovasc. Genet. 2(6), 607-613 (2009). doi: 10.1161/CIRCGENETICS.109.870410
122. G. Cianciolo, G. La Manna, G. Donati, E. Persici, A. Dormi, M.L. Cappuccilli, S. Corsini, R. Fattori, V. Russo, V. Nastasi, L. Coli, M. Wratten, S. Stefoni, Coronary calcifications in end-stage renal disease patients: a new link between osteoprotegerin, diabetes and body mass index? Blood Purif. 29(1), 13-22 (2010). doi: 10.1159/000245042
123. D.P. Lorant, M. Grujicic, C. Hoebaus, J.M. Brix, F. Hoellerl, G. Schernthaner, R. Koppensteiner, G.H. Schernthaner, Fetuin-A levels are increased in patients with type 2 diabetes and peripheral arterial disease. Diabetes Care 34(1), 156-161 (2011). doi: 10.2337/dc10-0788